flâneur

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions | GSK

gsk.com · 1,275 words · saved by 1 readers

Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks.

06 April 2020 GSK and Vir Biotechnology enter collaboration to find coronavirus solutions For media and investors only Issued: London, UK and San Francisco, US Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks Promising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five months GSK to make equity investment of $250 million in Vir GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agre

related reading